Mesoblast (ASX:MSB) onboarded ten transplant centers in the US for the supply of Ryoncil for the treatment of steroid-refractory acute graft versus host disease during the March quarter, and the firm plans to recruit ten more priority transplant centers during the June quarter, according to a Wednesday Australian bourse filing.

The firm brought on board a team of nine key account managers in the last week of April, who will focus on onboarding the remaining 35 priority transplant centers, accounting for 80% of US pediatric transplants.

It also secured a Type B meeting with the US Food and Drug Administration scheduled for the June quarter to discuss the accelerated approval pathway for Revascor, a candidate for the treatment of patients with ischemic chronic heart failure with reduced ejection fraction and inflammation.

Its shares fell 2% in recent trading on Wednesday.